Effects of ritanserin on the 3,4-methylenedioxymethamphetamine-induced decrease in striatal serotonin concentration and on the increase in striatal neurotensin and dynorphin A concentrations
by
concentrations. Johnson M, Bush LG, Hanson GR, Gibb JW.
Department of Pharmacology and Toxicology,
University of Utah, Salt Lake City 84112.
Biochem Pharmacol 1993 Aug 17;46(4):770-2


ABSTRACT

The concentration of serotonin (5-HT) measured in rat striatum was reduced to 75% of control 1 week after a single subcutaneous administration of dl-3,4-methylenedioxymethamphetamine (MDMA, 20 mg/kg). This decrease was prevented by pretreating the animals with ritanserin. Eighteen hours after MDMA (20 mg/kg), striatal concentrations of neurotensin-like immunoreactivity (NTLI) and of dynorphin A-like immunoreactivity (DLI) were increased to 250 and 487% of control, respectively, but ritanserin failed to prevent these changes. This study supports a role for 5-HT2 receptors in the mechanism by which a single high dose of MDMA induces neuronal damage to the serotonergic system, but not the MDMA-induced increase in central NTLI and DLI concentrations.

5-HT1a
5-HT1b
5-HT2c
History
Ketanserin
MDMA/MDE
Controversies
Protect and survive
Humans are not rats
Ecstasy and tryptophan
Ecstasy and MDL 100,907
Ecstasy and serotonin synthesis
Ecstasy and the serotonin receptors
Serotonin, GABA and dopamine release


Refs
and further reading

HOME
HedWeb
Nootropics
erythroxylum-coca.com
Future Opioids
BLTC Research
MDMA/Ecstasy
Superhapiness?
Utopian Surgery?
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World

The Good Drug Guide
The Good Drug Guide

The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family